Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
15
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| KELLY JUSTYNA | Chief Operating Officer | 8 | $0 | $0 | 2023-12-27 |
| JENSEN JESSICA D. | EVP Clinical Development | 10 | $0 | $0 | 2023-12-27 |
| HOGUE GERALD L. | Director | 12 | $25.0K | $0 | 2023-12-27 |
| MCCANN JOE A. | Chief Executive Officer | 9 | $14.3K | $0 | 2023-12-27 |
| MARGOLIN YAEL | Director | 8 | $11.2K | $0 | 2023-12-27 |
| GOODMAN JONATHAN R. | Director | 13 | $38.0K | $0 | 2023-12-27 |
| DEMERS WILLIAM L. | Chief Financial Officer | 8 | $0 | $0 | 2023-12-27 |
| FLESHNER NEIL E. | Chief Medical Officer | 14 | $0 | $4.24M | 2023-12-27 |
| Malik Rajesh | Director | 8 | $24.6K | $0 | 2023-12-27 |
| Lubner David Charles | Director | 9 | $24.7K | $0 | 2023-12-27 |
| SILBER ALLAN C | Executive Chairman | 18 | $311.2K | $0 | 2023-12-27 |
| BVF INC/IL | Other | 3 | $0 | $213.66M | 2023-12-18 |
| Martell Bridget A | Director | 1 | $0 | $0 | 2023-06-13 |
| GILMOUR MARGARET E. | Director | 2 | $0 | $0 | 2021-07-06 |
| GOTTLIEB MICHAEL M. | Chief Commercial Officer | 2 | $0 | $0 | 2021-07-06 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| MARGOLIN YAEL | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| MARGOLIN YAEL | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| MARGOLIN YAEL | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | D To issuer deriv | 2023-12-27 | 2023-12-27 | 537,322 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | D To issuer deriv | 2023-12-27 | 2023-12-27 | 332,476 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | D To issuer deriv | 2023-12-27 | 2023-12-27 | 6,787 | — | $0 | 0 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 16,767 | — | $0 | 0 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 105,360 | — | $0 | 0 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 131,355 | — | $0 | 0 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 179,362 | — | $0 | 0 | SEC↗ |
| Lubner David Charles | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| Lubner David Charles | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| Lubner David Charles | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| Malik Rajesh | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| Malik Rajesh | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| Malik Rajesh | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| HOGUE GERALD L. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 17,936 | — | $0 | 0 | SEC↗ |
| HOGUE GERALD L. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| HOGUE GERALD L. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| HOGUE GERALD L. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 60,234 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 84,257 | — | $0 | 0 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | D To issuer deriv | 2023-12-27 | 2023-12-27 | 461,250 | — | $0 | 0 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | D To issuer deriv | 2023-12-27 | 2023-12-27 | 136,055 | — | $0 | 0 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | D To issuer deriv | 2023-12-27 | 2023-12-27 | 213,301 | — | $0 | 0 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | D To issuer deriv | 2023-12-27 | 2023-12-27 | 13,766 | — | $0 | 0 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | D To issuer deriv | 2023-12-27 | 2023-12-27 | 125,553 | — | $0 | 0 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 381,795 | — | $0 | 0 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 692,643 | — | $0 | 0 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 26,904 | — | $0 | 0 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 98,358 | — | $0 | 0 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 77,958 | — | $0 | 0 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 70,000 | — | $0 | 0 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | D To issuer deriv | 2023-12-27 | 2023-12-27 | 4,932 | — | $0 | 0 | SEC↗ |
| GOODMAN JONATHAN R. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 35,872 | — | $0 | 0 | SEC↗ |
| GOODMAN JONATHAN R. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| GOODMAN JONATHAN R. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| GOODMAN JONATHAN R. | Director | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| MARGOLIN YAEL | Director | D To issuer | 2023-12-27 | 2023-12-27 | 1,710 | — | $0 | 0 | SEC↗ |
| Lubner David Charles | Director | D To issuer | 2023-12-27 | 2023-12-27 | 3,600 | — | $0 | 0 | SEC↗ |
| Lubner David Charles | Director | U Tender | 2023-12-26 | 2023-12-27 | 35,400 | — | $0 | 3,600 | SEC↗ |
| Malik Rajesh | Director | U Tender | 2023-12-26 | 2023-12-27 | 3,700 | — | $0 | 0 | SEC↗ |
| HOGUE GERALD L. | Director | U Tender | 2023-12-26 | 2023-12-27 | 21,596 | — | $0 | 0 | SEC↗ |
| GOODMAN JONATHAN R. | Director | U Tender | 2023-12-26 | 2023-12-27 | 41,872 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | U Tender | 2023-12-22 | 2023-12-27 | 4,035,655 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | U Tender | 2023-12-22 | 2023-12-27 | 38,087 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | U Tender | 2023-12-22 | 2023-12-27 | 71,744 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | U Tender | 2023-12-22 | 2023-12-27 | 4,268,605 | — | $0 | 0 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | U Tender | 2023-12-22 | 2023-12-27 | 313,884 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | U Tender | 2023-12-22 | 2023-12-27 | 233,171 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | U Tender | 2023-12-22 | 2023-12-27 | 358 | — | $0 | 0 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | U Tender | 2023-12-22 | 2023-12-27 | 2,773,045 | — | $0 | 0 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | U Tender | 2023-12-22 | 2023-12-27 | 3,494,153 | — | $0 | 0 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | U Tender | 2023-12-22 | 2023-12-27 | 2,160 | — | $0 | 0 | SEC↗ |
| BVF INC/IL | Other | S Sale | 2023-12-18 | 2023-12-20 | 8,974,245 | $12.45 | $111.73M | 0 | SEC↗ |
| BVF INC/IL | Other | S Sale | 2023-12-18 | 2023-12-20 | 7,290,667 | $12.45 | $90.77M | 0 | SEC↗ |
| BVF INC/IL | Other | S Sale | 2023-12-18 | 2023-12-20 | 896,366 | $12.45 | $11.16M | 0 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | G Gift | 2023-11-06 | 2023-11-07 | 120,000 | — | $0 | 3,494,153 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | G Gift | 2023-11-03 | 2023-11-07 | 500,000 | — | $0 | 38,087 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | G Gift | 2023-10-31 | 2023-11-02 | 250,000 | — | $0 | 2,773,045 | SEC↗ |
| Martell Bridget A | Director | A Award deriv | 2023-06-13 | 2023-06-14 | 80,503 | — | $0 | 80,503 | SEC↗ |
| Lubner David Charles | Director | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| Malik Rajesh | Director | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| MARGOLIN YAEL | Director | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| HOGUE GERALD L. | Director | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | A Award deriv | 2023-03-28 | 2023-03-30 | 131,355 | — | $0 | 131,355 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award deriv | 2023-03-28 | 2023-03-30 | 84,257 | — | $0 | 84,257 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | A Award deriv | 2023-03-28 | 2023-03-30 | 136,055 | — | $0 | 136,055 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | A Award deriv | 2023-03-28 | 2023-03-30 | 98,358 | — | $0 | 98,358 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | A Award deriv | 2023-03-28 | 2023-03-30 | 692,643 | — | $0 | 692,643 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | A Award deriv | 2023-03-28 | 2023-03-30 | 537,322 | — | $0 | 537,322 | SEC↗ |
| HOGUE GERALD L. | Director | M Exercise deriv | 2023-03-21 | 2023-03-23 | 17,936 | — | $0 | 17,936 | SEC↗ |
| HOGUE GERALD L. | Director | M Exercise | 2023-03-21 | 2023-03-23 | 17,936 | $6.97 | $125.0K | 21,596 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | P Buy | 2022-11-29 | 2022-11-30 | 2,160 | $6.64 | $14.3K | 3,616,313 | SEC↗ |
| Malik Rajesh | Director | P Buy | 2022-11-28 | 2022-11-28 | 3,700 | $6.66 | $24.6K | 3,700 | SEC↗ |
| HOGUE GERALD L. | Director | P Buy | 2022-11-25 | 2022-11-28 | 3,660 | $6.82 | $25.0K | 3,660 | SEC↗ |
| Lubner David Charles | Director | P Buy | 2022-11-23 | 2022-11-28 | 3,600 | $6.85 | $24.7K | 3,600 | SEC↗ |
| MARGOLIN YAEL | Director | P Buy | 2022-11-21 | 2022-11-23 | 1,710 | $6.56 | $11.2K | 1,710 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | P Buy | 2022-11-18 | 2022-11-21 | 22,397 | $6.50 | $145.6K | 4,268,605 | SEC↗ |
| GOODMAN JONATHAN R. | Director | P Buy | 2022-11-18 | 2022-11-21 | 6,000 | $6.33 | $38.0K | 41,872 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | P Buy | 2022-11-17 | 2022-11-21 | 27,603 | $6.00 | $165.6K | 4,246,208 | SEC↗ |
| Malik Rajesh | Director | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| MARGOLIN YAEL | Director | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| Lubner David Charles | Director | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| HOGUE GERALD L. | Director | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | S Sale | 2022-05-25 | 2022-05-26 | 564,204 | $7.51 | $4.24M | 3,023,045 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | A Award deriv | 2022-04-01 | 2022-04-05 | 13,766 | — | $0 | 13,766 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | A Award deriv | 2022-03-29 | 2022-03-31 | 381,795 | — | $0 | 381,795 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award deriv | 2022-03-29 | 2022-03-31 | 60,234 | — | $0 | 60,234 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | A Award deriv | 2022-03-29 | 2022-03-31 | 105,360 | — | $0 | 105,360 | SEC↗ |
| SILBER ALLAN C | Executive Chairman | A Award deriv | 2022-03-29 | 2022-03-31 | 332,476 | — | $0 | 332,476 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | A Award deriv | 2022-03-29 | 2022-03-31 | 77,958 | — | $0 | 77,958 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | A Award deriv | 2022-03-29 | 2022-03-31 | 213,301 | — | $0 | 213,301 | SEC↗ |
| KELLY JUSTYNA | Chief Operating Officer | A Award deriv | 2021-12-09 | 2021-12-10 | 70,000 | — | $0 | 70,000 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| GOTTLIEB MICHAEL M. | Chief Commercial Officer | A Award deriv | 2021-07-06 | 2021-07-08 | 48,000 | — | $0 | 48,000 | SEC↗ |
| HOGUE GERALD L. | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | A Award deriv | 2021-07-06 | 2021-07-08 | 16,767 | — | $0 | 16,767 | SEC↗ |
| GILMOUR MARGARET E. | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | A Award deriv | 2021-07-06 | 2021-07-08 | 461,250 | — | $0 | 461,250 | SEC↗ |
| Lubner David Charles | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Malik Rajesh | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MARGOLIN YAEL | Director | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award | 2021-06-30 | 2022-02-08 | 35,872 | — | $0 | 35,872 | SEC↗ |
| DEMERS WILLIAM L. | Chief Financial Officer | A Award deriv | 2021-06-30 | 2021-06-30 | 179,362 | — | $0 | 179,362 | SEC↗ |
| GILMOUR MARGARET E. | Director | A Award deriv | 2021-06-30 | 2021-06-30 | 35,872 | — | $0 | 35,872 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award deriv | 2021-06-30 | 2021-06-30 | 35,872 | — | $0 | 35,872 | SEC↗ |
| HOGUE GERALD L. | Director | A Award deriv | 2021-06-30 | 2021-06-30 | 35,872 | — | $0 | 35,872 | SEC↗ |
| JENSEN JESSICA D. | EVP Clinical Development | A Award deriv | 2021-06-30 | 2021-06-30 | 125,553 | — | $0 | 125,553 | SEC↗ |
| SILBER ALLAN C | Director | A Award deriv | 2021-06-30 | 2021-06-30 | 6,787 | — | $0 | 6,787 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award | 2021-06-30 | 2021-06-30 | 3,587,249 | — | $0 | 3,587,249 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award | 2021-06-30 | 2021-06-30 | 358 | — | $0 | 358 | SEC↗ |
| FLESHNER NEIL E. | Chief Medical Officer | A Award | 2021-06-30 | 2021-06-30 | 233,171 | — | $0 | 233,171 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award | 2021-06-30 | 2021-06-30 | 35,872 | — | $0 | 35,872 | SEC↗ |
| GOODMAN JONATHAN R. | Director | A Award | 2021-06-30 | 2021-06-30 | 21,523 | — | $0 | 21,523 | SEC↗ |
| GOTTLIEB MICHAEL M. | Chief Commercial Officer | A Award | 2021-06-30 | 2021-06-30 | 1,156,887 | — | $0 | 1,156,887 | SEC↗ |
| MCCANN JOE A. | Chief Executive Officer | A Award | 2021-06-30 | 2021-06-30 | 3,614,153 | — | $0 | 3,614,153 | SEC↗ |
| SILBER ALLAN C | Director | A Award | 2021-06-30 | 2021-06-30 | 71,744 | — | $0 | 71,744 | SEC↗ |
| SILBER ALLAN C | Director | A Award | 2021-06-30 | 2021-06-30 | 4,218,605 | — | $0 | 4,218,605 | SEC↗ |
| SILBER ALLAN C | Director | A Award | 2021-06-30 | 2021-06-30 | 4,035,655 | — | $0 | 4,035,655 | SEC↗ |
| SILBER ALLAN C | Director | A Award | 2021-06-30 | 2021-06-30 | 538,087 | — | $0 | 538,087 | SEC↗ |